ALTAFLUOR

Manufacturer
Altaire Pharmaceuticals Inc.
Effective date
2017-12-06
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
5
Source
full-release
Hydrated at
2026-05-31 20:45:30

Label at a glance#

ProductALTAFLUOR
Active ingredientFLUORESCEIN SODIUM, BENOXINATE HYDROCHLORIDE
Label structure14 sections

Indications and uses

Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is indicated for ophthalmic procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.

Dosage and administration

Instill 1 to 2 drops of Altafluor Benox in the eye as needed.

Storage and handling

Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is a sterile, yellow to orange-red solution supplied in a 5 mL glass bottle with a sterilized dropper. NDC #59390-218-05 Storage : Store in refrigerator at 2° to 8°C (36° to 46°F).  After opening, Altafluor Benox can be stored up to one month if stored at room temperature or until the expiration date on the bottle if s...

Label contents#

Full prescribing information#

1       INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is indicated for ophthalmic procedures requiring a disclosing agent in combination with a topical ophthalmic anesthetic agent.

2       DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Instill 1 to 2 drops of Altafluor Benox in the eye as needed.

3       DOSAGE FORMS AND STRENGTHS:

DOSAGE FORMS & STRENGTHS SECTION

Altafluor Benox is a yellow to orange-red ophthalmic solution containing fluorescein sodium 2.5 mg/mL (0.25%) and benoxinate hydrochloride 4 mg/mL (0.4%).

4       CONTRAINDICATIONS:

CONTRAINDICATIONS SECTION

Altafluor Benox is contraindicated in patients with known hypersensitivity to any component of this product.

5       WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Corneal Toxicity

SPL UNCLASSIFIED SECTION

Prolonged use or abuse may lead to corneal epithelial toxicity which may manifest as epithelial defects and progress to permanent corneal opacification with accompanying visual loss.

5.2 Corneal Injury Due to Insensitivity

SPL UNCLASSIFIED SECTION

Patient should not touch the eye for approximately 20 minutes after using this anesthetic as accidental injuries can occur due to insensitivity of the eye.

6       ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following ocular adverse reactions are described elsewhere in the labeling:

The following adverse reactions have been identified following use of fluorescein sodium and benoxinate hydrochloride ophthalmic solution 0.25% / 0.4%: ocular hyperemia, burning, stinging, eye irritation, blurred vision and punctate keratitis. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

8       USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Risk Summary 

There are no available data on the use of Altafluor Benox in pregnant women to inform any drug associated risk. Adequate animal reproduction studies have not been conducted with fluorescein sodium and/or benoxinate hydrochloride. Altafluor Benox should be given to a pregnant woman only if clearly needed.

8.2 Lactation

LACTATION SECTION

Risk Summary  

There are no data on the presence of fluorescein sodium or benoxinate hydrochloride in human milk after ocular administration of Altafluor Benox, the effects on the breastfed infant, or the effects on milk production.

The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for Altafluor Benox and any potential adverse effects on the breastfed infant from Altafluor Benox.

8.4 Pediatric Use

PEDIATRIC USE SECTION

The safety and effectiveness of Altafluor Benox have been established for pediatric patients. Use of Altafluor Benox is supported in pediatric patients by evidence from adequate and well controlled studies.

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

11       DESCRIPTION

DESCRIPTION SECTION

Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is a sterile disclosing agent in combination with a short-acting ester anesthetic for topical ophthalmic use.

Fluorescein sodium is represented by the following structural formula:  

      Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4% is a disclosing agent with rapid anesthetic action of short duration. Fluorescein Sodium is r...Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution USP, 0.25%/0.4% is a disclosing agent with rapid anesthetic action of short duration. Fluorescein Sodium is r...

C20H10Na2O5                                                   Mol. Wt. 376.27

Chemical Name: Spiro [isobenzofuran-1 (3H),9’-9[9H] xanthene]-3-one, 3’,6’ dihydroxy, disodium salt.

Benoxinate hydrochloride is represented by the following structural formula:

      Benoxinate Hydrochloride is represented by the following structural formula:Benoxinate Hydrochloride is represented by the following structural formula:

C17H28N2O3 • HCl                                                 Mol. Wt. 344.88

Chemical Name: 2-(Diethylamino) etyl 4-amino-3-butoxybenzoate monohydrochloride.

Each mL contains: Actives: fluorescein sodium 2.5 mg (0.25%) equivalent to fluorescein 2.2 mg (0.22%), benoxinate hydrochloride 4 mg (0.4%) equivalent to benoxinate 3.6 mg (0.36%); Inactives: povidone, hydrochloric acid, boric acid, sodium hydroxide, water for injection. Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (4.3 – 5.3). Preservative: chlorobutanol 11mg (1.1%).

12.       CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

This product is the combination of a disclosing agent with a rapidly acting ester anesthetic of short duration.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic effect may be extended by subsequent administration 10-20 minutes after the last administration.

13       NONCLINICAL TOXICOLOGY

NONCLINICAL TOXICOLOGY SECTION

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies to evaluate the carcinogenic potential of Altafluor Benox have not been conducted.

14       CLINICAL STUDIES

CLINICAL STUDIES SECTION

Controlled clinical studies in adults and pediatric patients have demonstrated that topical administration of fluorescein sodium and benoxinate hydrochloride ophthalmic solution 0.25%/0.4% enables visualization and corneal anesthesia sufficient to enable applanation tonometry, tear fluid dynamics evaluation and short conjunctival and corneal procedures. Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration.

16       HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Altafluor Benox (fluorescein sodium and benoxinate hydrochloride ophthalmic solution) 0.25%/0.4% is a sterile, yellow to orange-red solution supplied in a 5 mL glass bottle with a sterilized dropper.

NDC #59390-218-05

Storage: Store in refrigerator at 2° to 8°C (36° to 46°F).  After opening, Altafluor Benox can be stored up to one month if stored at room temperature or until the expiration date on the bottle if stored in refrigerated conditions. Keep tightly closed.

17       PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Accidental Injury Precaution

Advise patients not to touch their eyes for approximately 20 minutes after application. Their eyes will be insensitive due to the effect of the anesthetic, and care should be taken to avoid accidental injuries.

Rev. 12/2017                                   

Manufactured by:
ALTAIRE Pharmaceuticals, Inc.                                          
Aquebogue, NY 11931

PRINCIPAL DISPLAY PANEL

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 59390-218-05
ALTAFLUOR
BENOX
Fluorescein Sodium and
Benoxinate Hydrochloride
Ophthalmic Solution, USP 
0.25%/0.4%
(Sterile)
5 mL
Rx Only

NDC 59390-218-05 ALTAFLUOR BENOX Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, USP 0.25%/0.4% (Sterile) 5 mL Rx OnlyNDC 59390-218-05 ALTAFLUOR BENOX Fluorescein Sodium and Benoxinate Hydrochloride Ophthalmic Solution, USP 0.25%/0.4% (Sterile) 5 mL Rx Only

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
2099522Altafluor 0.4 % / 0.25 % Ophthalmic SolutionPSN5
2099132benoxinate HCl 0.4 % / fluorescein sodium 0.25 % Ophthalmic SolutionPSN5
2099522benoxinate hydrochloride 4 MG/ML / fluorescein sodium 2.5 MG/ML Ophthalmic Solution [Altafluor]SBD5
2099132benoxinate hydrochloride 4 MG/ML / fluorescein sodium 2.5 MG/ML Ophthalmic SolutionSCD5
2099522Altafluor (benoxinate HCl 0.4 % / fluorescein sodium 0.25 % ) Ophthalmic DropsSY5
2099132benoxinate hydrochloride 0.4 % / fluorescein sodium 0.25 % Ophthalmic DropsSY5

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
FLUORESCEIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
8f43a274-9585-47cb-b427-0eb3e578384dProduct name120250623
4a998fa9-995e-4ea5-97ef-93a559305758Product name120200706
c94ccba7-2a03-4a3e-a891-d62a57340fb2Product name120180215

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
59390-218-05ALTAFLUOR5 mL in 1 BOTTLE, DROPPERSOLUTION55

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
59390-218ALTAFLUOR (FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE) SOLUTION [ALTAIRE PHARMACEUTICALS INC.]5Current NDC, Legacy NDC, 1 package rows20221203_54017304-e680-4129-b52a-69cb9810af76.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
59390-218-05ML - Milliliter59390-218a64d4785-c6d2-46e3-8fcb-f952d523421812018-07-03

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 12 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
59390-21859390-218-05

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 8 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N208582-001ALTAFLUOR BENOXBENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1484e616aacf4f…
2026-08-18 06:07:402026-07N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1431067a03dcf5…
2025-08-23 18:47 UTC2025-08N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-146a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1403ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-142680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-145bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1479d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-141e350fbaab3a…
2024-05-31 18:47 UTC2024-05N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-148072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-145c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-145d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-144b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1474a2ff9319b5…
2022-03-09 01:35 UTC2022-03N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-1487673890dc5c…
2021-03-12 10:30 UTC2021-03N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-145aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-148869cabd3fbd…
2020-11-12 02:37 UTC2020-11N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14c0c555d07b60…
2019-12-14 00:12 UTC2019-12N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-143f01610625f2…
2019-09-15 20:21 UTC2019-09N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14b00525d2431f…
2019-07-19 19:46 UTC2019-07N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-146a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-141c564ffb4f44…
2023-12-20 04:57 UTC2023-12N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-149b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-143f0d92c62455…
2023-05-13 08:27 UTC2023-05N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14053a50430f4f…
2023-01-26 05:58 UTC2023-01N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-143bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-143a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N208582-001ALTAFLUOR BENOX0.4%;0.25%SOLUTION/DROPS / OPHTHALMICRLD, RS2017-12-14f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
ALTAFLUORFLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDEAltaire Pharmaceuticals Inc.54017304-e680-4129-b52a-69cb9810af762017-12-06Warnings, Adverse reactionsExact identifier
ndc (package): 59390-218-05
ndc (product): 59390-218
ndc11 (package): 59390021805
spl id: 22a50c28-e476-4966-b68c-065a4b8e157f
spl set id: 54017304-e680-4129-b52a-69cb9810af76

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.